Viveve CONSUMABLES AND RECERTIFICATION

Does the manufacturer Viveve charge the new owner a ONE TIME equipment RECERTIFICATION FEE for the purchase of consumables and service? Unknown

Consumables Needed: Singe Use Treatment Tip

Tip Cost: $500

Viveve PRODUCT SPECIFICATIONS

Laser Type:Radio Frequency, Monopolar Radio Frequency (CMRF)

Energy:90 J/cm2

Cooling:Cryogen

The Viveve System provides sustained tissue tightening and strengthening by substantially heating the tissue at depth. The Viveve System’s patented, cryogen-cooled monopolar radiofrequency (CMRF) is unique in its ability to deliver volumetric heat (90 J/cm2) in order to stimulate robust neocollagenesis. This can be accomplished in just ONE session.

The Viveve System is indicated for use in general surgery for electrocoagulation and hemostasis in the USA.

Quick Facts

Single Session

Cryogen-Cooled Monopolar Radiofrequency

One 30-45 minute session

Safe and comfortable

Clinically-proven

Respectable and discreet

Women worldwide are increasingly demanding nonsurgical treatments. However, there are a limited number of safe and effective technologies specifically designed for womens intimate health. Viveve provides clinically proven, innovative, nonsurgical treatments to improve womens intimate health.

The Viveve System delivers a single-session treatment to generate collagen and restore tissue. The dual mode VIVEVE TREATMENT COOLS AND PROTECTS THE SURFACE WHILE HEATING THE DEEPER TISSUE. The Viveve Treatment is both safe and effective.

The Viveve Treatment is delivered via the patented, cryogen-cooled monopolar radiofrequency (CMRF) device that rebuilds natural collagen. CMRF technology allows for depth of penetration while maintaining patient comfort and safety.

Viveve has completed enrolling a clinical trial for sexual dysfunction under an IDE.

Viveve also has a Stress Urinary Incontinence IDE under FDA review.

Viveve received approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018 to proceed with VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth.